225 related articles for article (PubMed ID: 32214853)
1. Low Prognostic Nutritional Index Predicts Poor Clinical Outcomes in Patients with Stage IIIB Non-small-cell Lung Carcinoma Undergoing Chemoradiotherapy.
Ozdemir Y; Topkan E; Mertsoylu H; Selek U
Cancer Manag Res; 2020; 12():1959-1967. PubMed ID: 32214853
[TBL] [Abstract][Full Text] [Related]
2. Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients.
Topkan E; Ozdemir Y; Kucuk A; Besen AA; Mertsoylu H; Sezer A; Selek U
PLoS One; 2019; 14(7):e0218627. PubMed ID: 31329602
[TBL] [Abstract][Full Text] [Related]
3. Baseline Low Prognostic Nutritional Index Predicts Poor Survival in Locally Advanced Nasopharyngeal Carcinomas Treated With Radical Concurrent Chemoradiotherapy.
Topkan E; Yucel Ekici N; Ozdemir Y; Besen AA; Mertsoylu H; Sezer A; Selek U
Ear Nose Throat J; 2021 Feb; 100(2):NP69-NP76. PubMed ID: 31184210
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of pretreatment Glasgow prognostic score in stage IIIB geriatric non-small cell lung cancer patients undergoing radical chemoradiotherapy.
Topkan E; Bolukbasi Y; Ozdemir Y; Besen AA; Mertsoylu H; Selek U
J Geriatr Oncol; 2019 Jul; 10(4):567-572. PubMed ID: 31178158
[TBL] [Abstract][Full Text] [Related]
5. Definitive concurrent chemoradiotherapy outcomes in Stage IIIB nonsmall cell lung cancer patients younger than 45 years: A retrospective analysis of 145 patients.
Topkan E; Guler OC; Ozdemir Y
J Cancer Res Ther; 2020; 16(4):757-763. PubMed ID: 32930115
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
Wang J; Liu Y; Mi X; Shao M; Liu L
Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
[TBL] [Abstract][Full Text] [Related]
7. Controlling Nutritional Status (CONUT) score is a prognostic marker in III-IV NSCLC patients receiving first-line chemotherapy.
Zhang Y; Kong FF; Zhu ZQ; Shan HX
BMC Cancer; 2023 Mar; 23(1):225. PubMed ID: 36894927
[TBL] [Abstract][Full Text] [Related]
8. Incidence and Impact of Pretreatment Tumor Cavitation on Survival Outcomes of Stage III Squamous Cell Lung Cancer Patients Treated With Radical Concurrent Chemoradiation Therapy.
Topkan E; Selek U; Ozdemir Y; Yildirim BA; Guler OC; Ciner F; Besen AA; Findikcioglu A; Ozyilkan O
Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1123-1132. PubMed ID: 29887509
[TBL] [Abstract][Full Text] [Related]
9. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
[TBL] [Abstract][Full Text] [Related]
10. Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
Taugner J; Käsmann L; Karin M; Eze C; Flörsch B; Guggenberger J; Li M; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Invest New Drugs; 2022 Feb; 40(1):163-171. PubMed ID: 34351518
[TBL] [Abstract][Full Text] [Related]
11. Impact of weight change during the course of concurrent chemoradiation therapy on outcomes in stage IIIB non-small cell lung cancer patients: retrospective analysis of 425 patients.
Topkan E; Parlak C; Selek U
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):697-704. PubMed ID: 24035331
[TBL] [Abstract][Full Text] [Related]
12. Combined systemic immune-inflammatory index and prognostic nutritional index predict outcomes in advanced non-small cell lung cancer patients receiving platinum-doublet chemotherapy.
Fan R; Chen Y; Xu G; Pan W; Lv Y; Zhang Z
Front Oncol; 2023; 13():996312. PubMed ID: 37077828
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic evaluation of nutritional indicators in patients with limited-stage small cell lung cancer].
Zhang JQ; Wang YY; Xu KP; Qi J; Wang X; Xu LM; Liu NN; Zhao LJ; Wang P
Zhonghua Zhong Liu Za Zhi; 2019 Dec; 41(12):937-942. PubMed ID: 31874552
[No Abstract] [Full Text] [Related]
15. Prognostic value of pretreatment prognostic nutritional index and lactated dehydrogenase in locally advanced nasopharyngeal carcinoma patients.
Xiong Y; Shi LL; Zhu LS; Peng G
Ann Palliat Med; 2021 Apr; 10(4):4122-4133. PubMed ID: 33832314
[TBL] [Abstract][Full Text] [Related]
16. The Prognostic Value of the Novel Global Immune-Nutrition-Inflammation Index (GINI) in Stage IIIC Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy.
Topkan E; Selek U; Pehlivan B; Kucuk A; Ozturk D; Ozdemir BS; Besen AA; Mertsoylu H
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760482
[TBL] [Abstract][Full Text] [Related]
17. High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer.
Topkan E; Kucuk A; Ozkan EE; Ozturk D; Besen AA; Mertsoylu H; Pehlivan B; Selek U
Discov Oncol; 2023 Dec; 14(1):230. PubMed ID: 38091179
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
[TBL] [Abstract][Full Text] [Related]
19. The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer.
Matsuura S; Serizawa S; Yamashita R; Morikawa K; Ito Y; Hiramatsu T; Mochizuki E; Tanaka K; Akiyama N; Tsukui M; Koshimizu N; Kosugi T
Ann Med; 2023 Dec; 55(1):2196089. PubMed ID: 37043179
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy.
Parlak C; Topkan E; Onal C; Reyhan M; Selek U
Radiat Oncol; 2012 Mar; 7():37. PubMed ID: 22429939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
